Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan
详细信息 查看全文
- 作者：Takeshi Kimura (1)
Takeshi Morimoto (2)
Yutaka Furukawa (3)
Yoshihisa Nakagawa (4)
Kazushige Kadota (5)
Masashi Iwabuchi (6)
Satoshi Shizuta (1)
Hiroki Shiomi (1)
Tomohisa Tada (1)
Junichi Tazaki (1)
Yoshihiro Kato (1)
Mamoru Hayano (1)
Mitsuru Abe (7)
Takashi Tamura (8)
Manabu Shirotani (9)
Shinji Miki (10)
Mitsuo Matsuda (11)
Mamoru Takahashi (12)
Katsuhisa Ishii (13)
Masaru Tanaka (14)
Takeshi Aoyama (15)
Osamu Doi (16)
Ryuichi Hattori (15)
Ryozo Tatami (17)
Satoru Suwa (18)
Akinori Takizawa (19)
Yoshiki Takatsu (20)
Masaaki Takahashi (21)
Hiroshi Kato (22)
Teruki Takeda (23)
Jong-Dae Lee (24)
Ryuji Nohara (25)
Hisao Ogawa (26)
Chuwa Tei (27)
Minoru Horie (28)
Hirofumi Kambara (16)
Hisayoshi Fujiwara (20)
Kazuaki Mitsudo (5)
Masakiyo Nobuyoshi (6)
Toru Kita (3) - 关键词：Stents ; Restenosis ; Thrombus
- 刊名：Cardiovascular Intervention and Therapeutics
- 出版年：2011
- 出版时间：September 2011
- 年：2011
- 卷：26
- 期：3
- 页码：234-245
- 全文大小：491KB
- 参考文献：1. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1. CrossRef
2. Lagerqvist B, James SK, Stenestrand U, Lindb?ck J, Nilsson T, Wallentin L, SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-9. CrossRef
3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-8. CrossRef
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, BASKET-LATE Investigators, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-1. CrossRef
5. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comparative meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-06. CrossRef
6. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393-02. CrossRef
7. Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008;118:1817-7. CrossRef
8. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent: data from an observational cohort study of drug-eluting versus bare-metal stents. J Am Coll Cardiol Interv. 2008;1:494-03.
9. Shishehbor MH, Goel SS, Kapadia SR, Bhatt DL, Kelly P, Raymond RE, et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol. 2008;52:1041-. CrossRef
10. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-Term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation. 2008;118:S199-09. CrossRef
11. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equation for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:932-. CrossRef
12. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-1. CrossRef
13. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-. CrossRef
14. The GUSTO Investigators. An inter-national randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-2. CrossRef
15. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987-5. CrossRef
16. Bar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53:1677-9. CrossRef
17. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-9. CrossRef
18. Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J. 2009;30:321-. CrossRef
19. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial Healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138-5. CrossRef
20. Wenaweser P, Daeman J, Zwahlen M, van Domburg R, Juni P, Vaina S, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134-0. CrossRef
21. Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol. 2010;106:329-6. CrossRef - 作者单位：Takeshi Kimura (1)
Takeshi Morimoto (2)
Yutaka Furukawa (3)
Yoshihisa Nakagawa (4)
Kazushige Kadota (5)
Masashi Iwabuchi (6)
Satoshi Shizuta (1)
Hiroki Shiomi (1)
Tomohisa Tada (1)
Junichi Tazaki (1)
Yoshihiro Kato (1)
Mamoru Hayano (1)
Mitsuru Abe (7)
Takashi Tamura (8)
Manabu Shirotani (9)
Shinji Miki (10)
Mitsuo Matsuda (11)
Mamoru Takahashi (12)
Katsuhisa Ishii (13)
Masaru Tanaka (14)
Takeshi Aoyama (15)
Osamu Doi (16)
Ryuichi Hattori (15)
Ryozo Tatami (17)
Satoru Suwa (18)
Akinori Takizawa (19)
Yoshiki Takatsu (20)
Masaaki Takahashi (21)
Hiroshi Kato (22)
Teruki Takeda (23)
Jong-Dae Lee (24)
Ryuji Nohara (25)
Hisao Ogawa (26)
Chuwa Tei (27)
Minoru Horie (28)
Hirofumi Kambara (16)
Hisayoshi Fujiwara (20)
Kazuaki Mitsudo (5)
Masakiyo Nobuyoshi (6)
Toru Kita (3)
1. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin, Kawahara-cho, Sakkyo-ku, Kyoto, 606-8507, Japan
2. Center for Medical Education and Clinical Epidemiology Unit, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3. Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
4. Division of Cardiology, Tenri Hospital, Tenri, Japan
5. Division of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
6. Division of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan
7. Division of Cardiology, Kyoto Medical Center, Kyoto, Japan
8. Division of Cardiology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
9. Division of Cardiology, Nara Hospital, Kinki University Faculty of Medicine, Nara, Japan
10. Division of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan
11. Division of Cardiology, Kishiwada City Hospital, Kishiwada, Japan
12. Division of Cardiology, Shimabara Hospital, Kyoto, Japan
13. Division of Cardiology, Kansai Denryoku Hospital, Osaka, Japan
14. Division of Cardiology, Osaka Red Cross Hospital, Osaka, Japan
15. Division of Cardiology, Shimada Municipal Hospital, Shimada, Japan
16. Division of Cardiology, Shizuoka General Hospital, Shizuoka, Japan
17. Division of Cardiology, Maizuru Kyosai Hospital, Maizuru, Japan
18. Division of Cardiology, Juntendo University Shizuoka Hospital, Shizuoka, Japan
19. Division of Cardiology, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
20. Division of Cardiology, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Japan
21. Division of Cardiology, Hamamatsu Rosai Hospital, Hamamatsu, Japan
22. Division of Cardiology, Nishi-Kobe Medical Center, Kobe, Japan
23. Division of Cardiology, Koto Memorial Hospital, Higashioumi, Japan
24. Division of Cardiology, University of Fukui Hospital, Fukui, Japan
25. Division of Cardiology, Kitano Hospital, Osaka, Japan
26. Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
27. Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan
28. Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science Hospital, Otsu, Japan
文摘
Long-term safety and efficacy of drug-eluting stents remains controversial. The CREDO-Kyoto registry cohort-2 is a physician-initiated non-company sponsored multi-center registry enrolling consecutive patients undergoing first coronary revascularization in 26 centers in Japan. We compared 3-year outcome between patients treated with sirolimus-eluting stent (SES) only (5092 patients) and bare-metal stent (BMS) only (5405 patients). SES-use as compared with BMS-use was associated with significantly lower adjusted risk for all-cause death [hazard ratio (HR) [95% confidence interval (CI)] 0.72 (0.59-.87), P?=?0.0007], which was mainly driven by the reduction in non-cardiac death [HR (95% CI) 0.64 (0.48-.85), P?=?0.002]. The risk of cardiac death [HR (95% CI) 0.82 (0.63-.07), P?=?0.15], myocardial infarction [HR (95% CI) 0.73 (0.51-.03), P?=?0.07] and definite stent thrombosis [HR (95% CI) 0.62 (0.35-.09), P?=?0.1] was not different between the two groups. Despite longer duration of thienopyridine administration, SES-use was associated with significantly lower risk for bleeding [HR (95% CI) 0.75 (0.6-.95), P?=?0.02] and similar risk for stroke [HR (95% CI) 1.0 (0.75-.34), P?=?1.0]. The risk for target-lesion revascularization (TLR) was markedly lower in the SES group [HR (95% CI) 0.42 (0.36-.48), P?<?0.0001]. The direction and magnitude of the effect of SES relative to BMS in patients presenting acute myocardial infarction (AMI) were similar to those in patients presenting otherwise. In conclusion, SES-use as compared with BMS-use was associated with marked reduction of TLR without any increases in death, myocardial infarction, stent thrombosis, stroke and bleeding in real world clinical practice regardless of clinical presentation including AMI.